Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025

CorMedix Inc. (NASDAQ:CRMD) is one of the best breakout stocks to invest in. On November 13, H.C. Wainwright’s Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD), citing strong DefenCath-driven revenue, Melinta acquisition synergies, and multiple growth catalysts including Rezzayo and TPN Phase 3 data in 2026. Despite TDAPA pricing risks, robust financials and pipeline potential support a favorable long-term outlook.

On November 12, CorMedix Inc. delivered strong third-quarter results, underscoring demand for specialty injectable therapies. It posted $104.3 million in net revenue and $130.8 million in pro forma net revenue, driven by higher utilization of DefenCath by outpatient dialysis customers.

Likewise, the company bounced back to profitability, generating $108.6 million in net income, or $1.26 per share. It was an improvement from a net loss of $2.8 million, or $0.05 per share, delivered in the same quarter last year. Growth in net income was driven by net product sales and a one-time tax benefit of $59.7 million.

CorMedix is betting on DefenCath, an FDA-approved catheter lock solution that offers significant risk reduction in catheter-related bloodstream infections (CRBSI). Consequently, it has raised its full-year 2025 pro forma net revenue to between $390 million and $410 million. It also expects net revenue to range between $115 million and $135 million. Following the acquisition of Melinta Therapeutics, the company expects to capture $30 million in synergy.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for infectious and inflammatory diseases. Its lead product is DefenCath, an antimicrobial catheter lock solution used to prevent catheter-related bloodstream infections in hemodialysis patients.

While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best AI Stocks to Buy Under $20 and Top 6 Steel Stocks to Buy Amid US Tariffs.

Disclosure: None. This article is originally published at Insider Monkey.